EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

The role of platelet P2Y 12 receptors in inflammation

William A E Parker iD, Robert F Storey iD

British Journal of Pharmacology · 2024-02 · 181 (4) · 515-531

DOI: 10.1111/bph.16256 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-11-02. Written by William A E Parker and 1 co-authors. Institution: Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK. Major MEDLINE topics: Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists. Cited 37 times so far (Crossref); 170 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: British Heart Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Inflammation is a complex pathophysiological process underlying many clinical conditions. Platelets contribute to the thrombo‐inflammatory response. Platelet P2Y 12 receptors amplify platelet activation, potentiating platelet aggregation, degranulation and shape change. The contents of platelet alpha granules, in particular, act directly on leucocytes, including mediating platelet–leucocyte aggregation and activation via platelet P‐selectin. Much evidence for the role of platelet P2Y 12 receptors in inflammation comes from studies using antagonists of these receptors, such as the thienopyridines clopidogrel and prasugrel, and the cyclopentyltriazolopyrimidine ticagrelor, in animal and human experimental models. These suggest that antagonism of P2Y 12 receptors decreases markers of inflammation with some evidence that this reduces incidence of adverse clinical sequelae during inflammatory conditions. Interpretation is complicated by pleiotropic effects such as those of the thienopyridines on circulating leucocyte numbers and of ticagrelor on adenosine reuptake. The available evidence suggests that P2Y 12 receptors are prominent mediators of inflammation and P2Y 12 receptor antagonism as a potentially powerful strategy in a broad range of inflammatory conditions. LINKED ARTICLES This article is part of a themed issue on Platelet purinergic receptor and non‐thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc

Subjects

MeSH terms (MEDLINE)

Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAnimalsHumansTicagrelorBlood PlateletsInflammationPlatelet AggregationPrasugrel HydrochlorideThienopyridinesReceptors, Purinergic P2Y12

Author keywords

P2Y12 receptorsinflammationleucocytesplatelets

Substances

TicagrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsPrasugrel HydrochlorideThienopyridinesReceptors, Purinergic P2Y12

Authors and institutions

  • Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
  • NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

ORCID profiles: William A E Parker, Robert F Storey

Funding

  • British Heart Foundation

Cite

APA

Parker, W. A. E., & Storey, R. F. (2024). The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology, 181(4), 515-531. https://doi.org/10.1111/bph.16256

Vancouver

Parker WAE, Storey RF. The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology. 2024;181(4):515-531. doi:10.1111/bph.16256

BibTeX
@article{Parker2024,
  author = {Parker, William A E and Storey, Robert F},
  title = {The role of platelet P2Y 12 receptors in inflammation},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {4},
  pages = {515--531},
  doi = {10.1111/bph.16256}
}
Start for free →